ASTRAZENECA

ASTRAZENECA
World Rank (Jan-01-2021)
93
Market Value (Jan-01-2021)
130.990 Billion USD
World Rank (Jan-2020)
72
Market Value (Jan 1st 2020)
135.300 Billion USD
World Rank (July-04-2020)
68
Market Cap (July-04-2020):
142.120 Billion USD
World Rank (Aug-22-2020):
69
Market Cap (Aug-22-2020)
145.037 Billion USD
Stock Category
FTSE 100
S&P EUROPE 350
Headquarters Country:
UK
Headquarters Region
Cambridge
ISIN Code:
GB0009895292
Company Business
Healthcare
Pharmaceutical
BioPharmaceuticals
Biotechnology
HealthCare Products
Technology
Number of Employees
70,600
Employee Count as on Date
As on 2020
CEO:
Pascal Soriot
Founded Year
1999
Stock Exchange
NYSE
Stockholm
LSE
Yahoo @ NYSE
Wikipedia
Twitter
Facebook
Bloomberg
Company Website:
Astrazeneca - Healthcare and Pharamaceutical Company
Business Sector:
Top Healthcare Companies in UK
Top Technology Companies in UK
Top Healthcare Companies in Europe
Top Technology Companies in Europe
Top Pharmaceutical Companies in Europe
Annual Revenue
ASTRAZENECA Annual Revenues for December-2020 ending is 26.21 Billion USD
Annual Operating Income
3.69 Billion USD for Year ending December-2020
Annual Net Income
ASTRAZENECA Annual Net Income for December-2020 ending is 3.19 Billion USD
Total Current Assets
15,563 Million USD as on Dec 2019
Total Assets
66.73 Billion USD for Year ending December-2020
Total Current Liabilities
18,117 Million USD as on Dec 2019
Total Liabilities
51.09 Billion USD for Year ending December-2020
Total Equity
15.64 Billion USD for Year ending December-2020
About Company Business:

ASTRAZENECA is UK Based Pharmaceutical and Bio-Technology Company. In the fight against COVID-19,Astrazeneca is one among World Top 5 Companies which is in advanced phase of Covid-19 testing in collaboration with the University of Oxford and are launching Phase III trials

Annual Results Summary:

AstraZeneca PLC - Annual Results - Revenue and Net Profit - in Million USD:

Year - Ending Revenue Operating Income Net Profit EPS (USD)
DEC-2020 26,217 3,694 3,196  
DEC-2019 24,384 1,702 1,335 0.52
DEC-2018 22,090 1,510 2,155 0.85
DEC-2017 22,465 2,292 3,001 1.19
Quarterly Results Summary:

AstraZeneca PLC - Quarterly Results - Revenue and Net Profit - in Million USD:

Quarter - Ending Revenue Net Profit EPS (USD)
SEP-2020 6,578 651 0.49
JUN-2020 6,275 837 0.56
MAR-2020 6,354 780 0.30
DEC-2019 6,664 313 0.12
SEP-2019 6,406 299 0.11
JUN-2019 5,823 130 0.05
MAR-2019 5,491 593 0.23

Comments

Oxford Vaccine Trials again resumed by Astrazeneca

Oxford Vaccine Trials again resumed by Astrazeneca after UK Regulatory Authorities had given permission to go ahead with trials. Post one person undergoing trials had fallen ill, Astrazeneca temporarily paused trials of Oxford Vaccine.

Then again after review, as UK health regulatory authorities had given permission to go ahead with trials, again Oxford Vaccine Trials started.

Russia vaccine and Oxford vaccine are two vaccines related to Covid-19, that are in most advance stages of testing.

Sun, 13/09/2020 - 14:51

Share it on Social Media